These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2973300)

  • 1. [Advantages of immediate coronary dilatation after thrombolysis using tissue-type plasminogen activator in acute myocardial infarction. A European Cooperative Group trial].
    Vahanian A
    Arch Mal Coeur Vaiss; 1988 May; 81 Spec No():39-43. PubMed ID: 2973300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.
    Bruna C; Rossetti G; Vado A; Racca E; Steffenino G; Dellavalle A; Ribichini F; Ferrero V; Menardi E; Uslenghi E
    G Ital Cardiol; 1998 Jan; 28(1):3-11. PubMed ID: 9493040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Usefulness of combination therapy of hybrid thrombolysis followed by back-up percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction].
    Mukawa H; Sone T; Tsuboi H; Kondo J; Kosokabe T; Uesugi M; Imai H
    J Cardiol; 2001 Apr; 37(4):181-9. PubMed ID: 11337927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the thrombolysis and angioplasty in acute myocardial infarction (TAMI) trials.
    Topol EJ
    Arch Mal Coeur Vaiss; 1988 May; 81 Spec No():45-9. PubMed ID: 2973302
    [No Abstract]   [Full Text] [Related]  

  • 5. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.
    Topol EJ; Califf RM; George BS; Kereiakes DJ; Abbottsmith CW; Candela RJ; Lee KL; Pitt B; Stack RS; O'Neill WW
    N Engl J Med; 1987 Sep; 317(10):581-8. PubMed ID: 2956516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The safety and efficacy of systemic salvage thrombolysis in acute myocardial infarct].
    Sarullo FM; Schicchi R; Schirò M; Americo L; Bonnì G; Faraone N; Di Pasquale P; Castello A; Mauri F
    Ital Heart J Suppl; 2000 Jan; 1(1):81-7. PubMed ID: 10832123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Platelet activation in the early phases of acute myocardial infarction].
    Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G
    Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of recombinant tissue-type plasminogen activator thrombolysis and primary coronary stenting after acute myocardial infarction.
    Chen B; Wang W; Zhao H; Hu D; Xu C; Zhao M; Lu M; Liu J; Wu C
    Chin Med J (Engl); 2003 Jan; 116(1):142-4. PubMed ID: 12667408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
    Bassand JP; Cariou R; Grollier G; Kragten J; Wolf JE; Heyndrickx GR
    Semin Thromb Hemost; 1999; 25 Suppl 2():69-75. PubMed ID: 10440428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of diltiazem during myocardial reperfusion: a randomized trial in acute myocardial infarction.
    Pizzetti G; Mailhac A; Li Volsi L; Di Marco F; Lu C; Margonato A; Chierchia SL
    Ital Heart J; 2001 Oct; 2(10):757-65. PubMed ID: 11721720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of low-dose mutant tissue-type plasminogen activator followed by planned rescue percutaneous transluminal coronary angioplasty as reperfusion therapy for acute myocardial infarction].
    Tsukahara K; Kimura K; Usui T; Okuda J; Kitamura Y; Kosuge M; Sano T; Tohyama S; Nemoto T; Yamanaka O; Yoshii Y; Tochikubo O; Umemura S
    J Cardiol; 2001 Mar; 37(3):143-50. PubMed ID: 11281054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.
    Steg PG; Bonnefoy E; Chabaud S; Lapostolle F; Dubien PY; Cristofini P; Leizorovicz A; Touboul P;
    Circulation; 2003 Dec; 108(23):2851-6. PubMed ID: 14623806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
    Sarullo FM; Pasquale PD; D'Alfonso G; Amerigo L; Cannizzaro S; Castello A
    Ital Heart J; 2001 Aug; 2(8):605-11. PubMed ID: 11577835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of percutaneous coronary intervention with antecedent mutant t-PA administration for acute myocardial infarction.
    Kurihara H; Matsumoto S; Tamura R; Yachiku K; Nakata A; Nakagawa T; Yoshino T; Matsuyama T
    Am Heart J; 2004 Apr; 147(4):E14. PubMed ID: 15077097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of thrombolytic therapy and direct percutaneous transluminal coronary angioplasty for acute myocardial infarction: prospective multicenter trial at 16 clinical centers in Ibaraki prefecture TUGMI. Tsukuba University Group for Myocardial Infarction].
    Noguchi Y; Yamaguchi I; Sugishita Y
    J Cardiol; 1996 Mar; 27(3):111-20. PubMed ID: 8865683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of intravenous thrombolysis prior to percutaneous coronary intervention in reperfusion therapy for acute myocardial infarction].
    Uto K; Ota Y; Mizuno M; Nakamura A; Nakajima R; Endoh Y; Kasanuki H
    J Cardiol; 2002 Dec; 40(6):241-8. PubMed ID: 12528645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hemorrhagic risk in intravenously administered thrombolytic treatment in acute myocardial infarction].
    Acar J; Dorent R; Vahanian A; Michel PL; Cormier B; Slama M; Cazaux P; Conard J; Verdy E; Samama M
    Arch Mal Coeur Vaiss; 1988 May; 81 Spec No():59-65. PubMed ID: 3142430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.
    Simoons ML; Arnold AE; Betriu A; de Bono DP; Col J; Dougherty FC; von Essen R; Lambertz H; Lubsen J; Meier B
    Lancet; 1988 Jan; 1(8579):197-203. PubMed ID: 2893037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.